Each filer's latest filing for G1933S101 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
He Wei-Wu
13D/A
|
58.8% |
5/18/2026
Event 5/18/2026
|
||
| WEI-WU HE, Ph.D. | 58.8% | |||
| Huiying Memorial Foundation | 3.1% | |||
| Emerging Technology Partners, LLC | 52.0% | |||
| ETP Global Fund L.P. | 3.7% | |||
| Etp Biohealth III Fund, L.P. | 1.5% | |||
| HE Family GRAT | 0.5% | |||
| ETP Global III Fund L.P. | 49.3% | |||
|
Panacea Innovation Ltd
13D/A
|
22.5% |
12/17/2025
Event 12/16/2025
|
||
| Panacea Venture Healthcare Fund II, L.P. | 22.0% | |||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 22.0% | |||
| Panacea Innovation Limited | 22.0% | |||
| James Huang | 22.5% | |||
|
James Huang
13G/A
|
13.8% |
7/23/2025
Event 6/30/2025
|
||
| Panacea Venture Healthcare Fund II, L.P. | 13.2% | |||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 13.2% | |||
| Panacea Innovation Limited | 13.2% | |||
| James Huang | 13.8% | |||
| Chen Zhenfeng M 13G | 11.0% |
11/26/2025
Event 9/30/2025
|
||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
|
9.2% |
2/17/2026
Event 12/31/2025
|
||
| Venrock Healthcare Capital Partners III, L.P. | 9.2% | |||
| VHCP Co-Investment Holdings III, LLC | 9.2% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 9.2% | |||
| VHCP Management III, LLC | 9.2% | |||
| VHCP Management EG, LLC | 9.2% | |||
| Nimish Shah | 9.2% | |||
| Bong Y. Koh | 9.2% | |||
|
Sparkle Byte Ltd
13D/A
|
5.0% |
1/20/2026
Event 9/30/2025
|
||
| Sparkle Byte Ltd | 5.0% | |||
| Snow Moon Ltd | 5.0% | |||
| Tianjin Jingran Management Center (Limited Partnership) | 5.0% | |||
| Beijing Hexie Kangjian Investment Center (Limited Partnership) | 5.0% | |||
| Beijing Hexie Tiancheng Investment Management Center (Limited Partnership) | 5.0% | |||
| He Xie Ai Qi Investment Management (Beijing) Co., Ltd. | 5.0% | |||
| Xizang Hexie Enterprise Management Co., Ltd. | 5.0% | |||
| Zhuhai Hexie Zhiyuan Management Consulting Co., Ltd. | 5.0% | |||
| Jianguang Li | 5.0% | |||
| Dongliang Lin | 5.0% | |||
| Jingbo Wang | 5.0% | |||
| Kuiguang Niu | 5.0% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
|
Ho Chi Sing
13D/A
|
4.8% |
1/20/2026
Event 9/30/2025
|
||
| IDG-Accel China Growth Fund III L.P. | 4.5% | |||
| IDG-Accel China III Investors L.P. | 4.5% | |||
| IDG-Accel China Growth Fund III Associates L.P. | 4.5% | |||
| IDG-Accel China Growth Fund GP III Associates Ltd. | 4.5% | |||
| Ho Chi Sing | 4.5% | |||
| Zhou Quan | 4.8% | |||
|
Foresite Capital Fund VI LP
13G/A
|
0% |
2/13/2026
Event 12/31/2025
|
||
| Foresite Capital Fund VI LP | 0% | |||
| Foresite Capital Management VI LLC | 0% | |||
| James Tananbaum | 0% | |||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 100 | $11 |
| 2026 Q2 | 1 | 100 | $17 |
| 2026 Q1 | 1 | 228 | $25 |
| 2025 Q4 | 16 | 1.25 M | $1.06M |
| 2025 Q3 | 22 | 2.61 M | $4.33M |
| 2025 Q2 | 25 | 2.26 M | $2.66M |
| 2025 Q1 | 24 | 2.74 M | $5.93M |
| 2024 Q4 | 23 | 2.66 M | $7.52M |
| 2024 Q3 | 21 | 1.32 M | $8.14M |
| 2024 Q2 | 24 | 354 k | $1.94M |
| 2024 Q1 | 22 | 255 k | $920k |
| 2023 Q4 | 19 | 277 k | $1.99M |
| 2023 Q3 | 20 | 345 k | $883k |
| 2023 Q2 | 20 | 450 k | $1.12M |
| 2023 Q1 | 21 | 930 k | $2.15M |
| 2022 Q4 | 1 | 100 | $179 |